- PR Newswire•2 days ago
FRANKLIN LAKES, N.J., Jan. 18, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a global medical technology company, announced today that it will host a live webcast of its Annual Meeting ...
- Zacks•3 days ago
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has made its Precise whole transcriptome analysis kits commercial available.
- PR Newswire•4 days ago
FRANKLIN LAKES, N.J., Jan. 17, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced the commercial availability of its new kits that provide an easier method to identify and quantify genetic information in individual cells for genomics-based research. The process of whole transcriptome analysis (WTA) is typically used by researchers in the discovery phase to determine if an under- or over-expression of certain genes are indicative of a specific set of physical characteristics, or phenotype. Being able to quantify RNA molecules that comprise genes is a critical early stage process to determine what makes healthy cells different from diseased cells, for example, or to gain a greater understanding of the underlying causes of cell differentiation.
BDX: Summary for Becton, Dickinson and Company C - Yahoo Finance
Becton, Dickinson and Company (BDX)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
|Day's range||172.03 - 174.34|
|52-week range||129.50 - 181.76|
Trade prices are not sourced from all markets
|PE ratio (TTM)||38.37|
|Dividend & yield||2.92 (1.68%)|
|1y target est||N/A|